Efficacy of oral acyclovir in the treatment of initial and recurrent genital herpes.  P Metabolic disposition of the acyclovir prodrug valacyclovir in the rat.

Goldberg  PBlum Salo  LS  N  JW Acyclovir: a decade later.  et al. ... Valacyclovir enhances acyclovir bioavailability compared with orally administered acyclovir.  MLovett It is most effective when started within 48 hours of symptom onset. All Rights Reserved.to download free article PDFs, Acyclovir is an antiviral drug that helps treat chickenpox, genital herpes, and shingles infections.  EAndersson  RCent  DHFife

Aoki, MD, University of Manitoba, Winnipeg; K. Beutner, MD, PhD, Solano Dermatology Associates, Vallejo, Calif; L. Bondesson, MD, Karolinska Hospital, Stockholm, Sweden; S. Borelli, MD, T. U. München, Munich, Germany; K. Bork, MD, Klinikum der Johannes-Gutenberg Universität, Mainz, Germany; B. Coble, University Hospital, Linköping, Sweden; L. Corey, MD, University of Washington, Seattle; E. Curless, MD, Bolton General Hospital, Bolton, England; B. M. Czametzki, MD, Universitätsklinikum Rudolf Virchow, Berlin, Germany; J. Douglas, MD, Denver Department of Public Health, Denver, Colo; L. Eron, MD, Infectious Disease Physicians Inc, Annandale, Va; J. Esmann, MD, Marselisborg Hospital, Aarhus, Denmark; K. Fife, MD, PhD, Indiana University Medical School, Indianapolis; C. Forszpaniak, MD, Diagnostic Services Inc, Naples, Fla; L. Goldberg, MD, Houston, Tex; A. Halsos, MD, Venerology Clinic, Health Council, Oslo, Norway; P. Hino, MD, Dermatology Center of Dallas, Dallas, Tex; H. J. Hulsebosch, MD, PhD, Academisch Medisch Centrum, Amsterdam, the Netherlands; R. H. Kaufman, MD, Baylor College of Medicine, Houston; H. Kessler, MD, Rush–Presbyterian–St Lukes Medical Center, Chicago, Ill; G. R. Kinghorn, MD, Royal Hallamshire Hospital, Sheffield, England; S. Kroon, MD, Odense Hospital, Odense, Denmark; T. Kurtz, DO, Des Moines, Iowa; W. Lang, MD, ViRx Inc, San Francisco, Calif; J. Lauharanata, MD, Helsinki University Central Hospital, Department of Dermatology/Venereology, Helsinki, Finland; L. Lefkowitz, MD, Vanderbilt School of Medicine, Nashville, Tenn; A. Martel, MD, University of Laval, St Foy, Quebec; C. McDonald, MD, Roger Williams Medical Center, Providence, RI; G. J. Mertz, MD, University of New Mexico, Albuquerque; P. Morel, MD, Hospital Saint Louis, Paris, France; R. Murphy, MD, Northwestern Memorial Hospital, Chicago; M. Negosanti, MD, Universita degli Studi, Bologna, Italy; A. Nilsen, MD, Haukeland Hospital, Bergen, Norway; J. Paavonen, MD, Helsinki University Central Hospital, Helsinki; P. Piot, MD, Institute of Tropical Medicine, Antwerp, Belgium; K. Ramsey, MD, University of South Alabama, Mobile; T. Rufli, MD, Kantonsspital, Basel, Switzerland; M. Ruhnek-Forsbeck, MD, Sophiahemmet, Stockholm; S. Sacks, MD, University of British Columbia, Vancouver, British Columbia; S. Safrin, MD, San Francisco General Hospital; J. Soltz-Szots, MD, Hospital Rudolfstiftung, Vienna, Austria; S. L. Spruance, MD, University of Utah, Salt Lake City; J. P. Stahl, MD, CHU de Grenoble, Grenoble, France; G. Stingi, MD, University Clinic of Dermatology, Vienna, Austria; A. Strand, MD, Akademiska Hospital, Uppsala, Sweden; P. Taylor, MD, Bristol Royal Infirmary, Bristol, England; R. N. Thin, MD, St Thomas' Hospital, London, England; S. Tyring, MD, PhD, University of Texas Medical Branch, Galveston; E. Van Hecke, MD, Universitair Zickenhuis RU Gent, Ghent, Belgium; M. Van Heenen, MD, Hopital Erasme, Brussels, Belgium; G. Vejlsgaard, MD, Rigshopitalet, Copenhagen, Denmark; J. Welch, MD, Kings College Hospital, London; A. M. Worm, MD, Bispebjerg Hospital, Copenhagen.Reprints: Stephen K. Tyring, MD, PhD, University of Texas Medical Branch, Department of Dermatology, Galveston, TX 77555-1019 (e-mail: Baseline Patient Characteristics and Disposition StatusPrimary Efficacy End Points: Length of Episode and Lesion Healing Time*Secondary Efficacy End Points: Duration of Pain and of Virus Shedding*Adverse Events Reported by 2% or More of Patients in Any Treatment GroupJohnson Three antiviral medications—valacyclovir, acyclovir, and famciclovir—are commonly prescribed to alleviate symptoms and reduce or prevent future outbreaks.

 DGoa  FHadgu  M

 RCBadger Duration and Severity of Pain and Discomfort  RLee  BMiller  THalsos Treatment of recurrent genital herpes simplex infections with oral acyclovir.  VNahmias  et al. Episodic twice-daily treatment for recurrent genital herpes.  JSeaber Corey Thin Other things that will trigger and outbreak for me: too much direct sun on my face and too much exposure to extreme cold on my face.  RENahmias